Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3526318 in Osteoarthritis Pain
NCT05080660Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LY3526318 in osteoarthritis (OA), sponsored by Eli Lilly and Company. Started Oct 2021; status: completed.
02
Drugs
LY3526318
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05080660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05080660.